Axoltis Pharma Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.94M

  • Investors
  • 6

Axoltis Pharma General Information

Description

Operator of a biotechnology company intended to treat patients suffering from severe neurological disorders. The company's drugs assist neural repair in order to treat patients with traumatic degenerative disorders of the central nervous system faced with high unmet medical needs, enabling patients to get treatment for neurodegenerative diseases and improve functional recovery and quality of life.

Contact Information

Website
www.axoltis.com
Formerly Known As
Neuronax
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 15 - 17, Rue du Pré de la Reine
  • 63100 Clermont-Ferrand
  • France
+33 04 00 00 00 00

Axoltis Pharma Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Axoltis Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 23-Feb-2023 $4.94M 000.00 000.00 Completed Clinical Trials - Phase 2
8. Later Stage VC 02-Apr-2021 00.000 000.00 000.00 Completed Clinical Trials - Phase 1
7. Later Stage VC 18-Jul-2020 00.000 00.00 000 Completed Clinical Trials - Phase 1
6. Later Stage VC 05-Mar-2019 00.00 00.000 00.000 Completed Clinical Trials - Phase 1
5. Later Stage VC 12-Oct-2017 00.000 00.000 00.00 Completed Clinical Trials - Phase 1
4. Later Stage VC 15-Jun-2016 00.000 00.000 00.00 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series A) 19-Dec-2014 00.000 00.000 00.000 Completed Clinical Trials - Phase 1
2. Later Stage VC 13-Jul-2013 $620K $620K 00.000 Completed Clinical Trials - Phase 1
1. Grant 01-Oct-2012 $772K Completed Clinical Trials - Phase 1
To view Axoltis Pharma’s complete valuation and funding history, request access »

Axoltis Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 00.000
Shares D 000,000 00.000000 000.00 000.00 00 000.00 00.000
Shares C 16,009 $5.386830 $161.6 $161.6 1x $161.6 2.12%
Ordinary 9,420 $5.386830 $215.47 $215.47 1x $215.47 1.25%
To view Axoltis Pharma’s complete cap table history, request access »

Axoltis Pharma Patents

Axoltis Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4190347-A1 Sco-spondin-derived polypeptides for treating biological barriers dysfunction Inactive 01-Dec-2021 000000000 0
CA-3239213-A1 Sco-spondin-derived polypeptides for treating biological barriers dysfunction Pending 01-Dec-2021 000000000
AU-2022399936-A1 Sco-spondin-derived polypeptides for treating biological barriers dysfunction Pending 01-Dec-2021 000000000
AU-2022306923-A1 Sco-spondin-derived polypeptides for enhancing synaptic transmission Pending 09-Jul-2021 00000000000
CA-3223638-A1 Sco-spondin-derived polypeptides for enhancing synaptic transmission Pending 09-Jul-2021 A61K38/1709
To view Axoltis Pharma’s complete patent history, request access »

Axoltis Pharma Executive Team (12)

Name Title Board Seat Contact Info
Yann Godfrin Ph.D Chief Executive Officer, President, Publication Director & Chairman
Sighild Lemarchant Ph.D Chief Scientific Officer
Luca Bolliger Ph.D Chief Business Officer & Advisor
Jérémy Caimi Administration & Finance Manager
Foucauld Pouet President of the Supervisory Board
You’re viewing 5 of 12 executive team members. Get the full list »

Axoltis Pharma Board Members (6)

Name Representing Role Since
François Miceli Sofimac Investment Managers Supervisory Board Member 000 0000
Gilles Avenard MD Self Board Member 000 0000
Isabelle Baillenx Self Board Observer 000 0000
Pierre-Olivier Goineau Self Member of Supervisory Board & Board Observer 000 0000
Yann Godfrin Ph.D Axoltis Pharma Chief Executive Officer, President, Publication Director & Chairman 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Axoltis Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axoltis Pharma Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Angelor Angel Group Minority 000 0000 000000 0
Auvergne Business Angels Angel Group Minority 000 0000 000000 0
FaDiese Venture Capital Minority 000 0000 000000 0
JEREMIE Auvergne Venture Capital Minority 000 0000 000000 0
Sofimac Investment Managers Growth/Expansion Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Axoltis Pharma FAQs

  • When was Axoltis Pharma founded?

    Axoltis Pharma was founded in 2003.

  • Who is the founder of Axoltis Pharma?

    Stephane Gobron Ph.D, Pierre-Yves Simonin, and Fabrice Cailloux Ph.D are the founders of Axoltis Pharma.

  • Who is the CEO of Axoltis Pharma?

    Yann Godfrin Ph.D is the CEO of Axoltis Pharma.

  • Where is Axoltis Pharma headquartered?

    Axoltis Pharma is headquartered in Clermont-Ferrand, France.

  • What is the size of Axoltis Pharma?

    Axoltis Pharma has 12 total employees.

  • What industry is Axoltis Pharma in?

    Axoltis Pharma’s primary industry is Drug Discovery.

  • Is Axoltis Pharma a private or public company?

    Axoltis Pharma is a Private company.

  • What is the current valuation of Axoltis Pharma?

    The current valuation of Axoltis Pharma is 000.00.

  • What is Axoltis Pharma’s current revenue?

    The current revenue for Axoltis Pharma is 000000.

  • How much funding has Axoltis Pharma raised over time?

    Axoltis Pharma has raised $17.6M.

  • Who are Axoltis Pharma’s investors?

    Angelor, Auvergne Business Angels, FaDiese, JEREMIE Auvergne, and Sofimac Investment Managers are 5 of 6 investors who have invested in Axoltis Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »